Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2021

View Archived Issues

Sinocelltech starts phase II/III development of SCTA-01 in COVID-19

First patient infused in phase I study of CD19 RPM CAR-T cell therapy

Krystal Biotech provides development updates for KB-407 and KB-408

Revolution Medicines targets SOS-1 with new compound RMC-0331 for RAS-driven cancers

Baricitinib improves hair regrowth in patients with alopecia areata in second BRAVE-AA trial

FDA places clinical hold on proposed phase II study of KVD-824

Positive interim data presented from phase I portion of the AUGMENT-101 study of SNDX-5613

FDA allows Vincerx Pharma to conduct phase Ib study of VIP-152 in CLL and Richter syndrome

Phase II study application for FB-704A in severe asthma receives approval in Taiwan

ECM2 mutation as a biomarker of response to ICIs in patients with melanoma

Discovery and preclinical characterization of novel KRAS G12C inhibitor, LY-3537982

SEP-363856 is associated with robust improvement in negative symptoms of schizophrenia

Sumitomo Dainippon Pharma patents new compounds for cancer

Fujifilm divulges FGFR inhibitors

New GTPase KRAS mutant inhibitors presented by BeiGene

Pivotal study evaluates ION-373 for Alexander disease

Medshine Discovery patent describes LSD1 inhibitors

King's College London presents adeno-associated viral vectors

Novel STING agonists for antitumor immunotherapy

New molecular imaging and therapy trials open at Hoag

FDA clears IND for phase I trial of Transcenta's bifunctional PD-L1/TGF-beta antibody TST-005

AZD-8853, a new anti-GDF15 antibody for cancer immunotherapy

Initiation of NOBLE Registry for Telix's TLX599-CDx SPECT in prostate cancer

CL-2020 studied for ARDS related to COVID-19 in Japan

Trevena's TRV-027 to be studied in REMAP-CAP study for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...